Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Recommends Granting a Marketing Authorisation for Generic Lenalidomide

Lenalidomide Accord is intended for the treatment of multiple myeloma
16 Aug 2018
Haematologic malignancies;  Anticancer agents & Biologic therapy

On 26 July 2018, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending granting a marketing authorisation for the medicinal product Lenalidomide Accord, intended for the treatment of multiple myeloma. 

The applicant for this medicinal product is Accord Healthcare Limited. 

Lenalidomide Accord will be available as capsules (2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg and 25 mg). The active substance of Lenalidomide Accord is lenalidomide, an immunomodulating agent (ATC code: L04AX04) that works in a number of different ways including cytokine modulation, induction of T-cell proliferation, anti-proliferation of multiple myeloma cells and inhibition of angiogenesis. 

Lenalidomide Accord is a generic of Revlimid which has been authorised in the EU since 14 June 2007. 

Studies have demonstrated the satisfactory quality of Lenalidomide Accord and its bioequivalence to the reference product Revlimid. 

The full indication is: 

  • Lenalidomide Accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.
  • Lenalidomide Accord as combination therapy is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.
  • Lenalidomide Accord in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. 

It is proposed that Lenalidomide Accord be prescribed by physicians experienced in the treatment of cancer. 

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission. 

Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion.

Last update: 16 Aug 2018

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings